Idiopathic Pulmonary Fibrosis (IPF)

IPF requires confirmation by an experienced interstitial lung disease (ILD) team. A multidisciplinary team (MDT) discussion is the standard of care. The Pulmonary Fibrosis Foundation (pulmonaryfibrosis.org) has a care center directory. Getting to an expert center early is the most important step.

Both Esbriet (pirfenidone) and Ofev (nintedanib) are FDA-approved for IPF and slow disease progression. Clinical guidelines recommend starting antifibrotic therapy in all eligible IPF patients regardless of disease severity. The earlier you start, the more lung function you preserve. Ask about generic pirfenidone for a lower-cost option.

Pulmonary function tests (PFTs) — especially forced vital capacity (FVC) — are the key measure of IPF progression. A baseline measurement lets you track disease stability. FVC decline of 10%+ over 12 months is associated with significantly increased mortality. Track your numbers at every follow-up visit.

Pulmonary rehab is evidence-based and dramatically improves quality of life, exercise tolerance, and breathlessness in IPF. Ask for a referral at your first visit. Medicare covers pulmonary rehab for eligible IPF patients.

Genentech's IPF Connect (Esbriet) and Boehringer Ingelheim's InControl (Ofev) programs provide co-pay assistance and disease management support. Ask your doctor about generic pirfenidone — it's substantially less expensive than branded Esbriet and clinically equivalent.

Idiopathic pulmonary fibrosis (IPF) is a specific type of chronic, progressive lung disease in which lung tissue becomes progressively thickened, stiff, and scarred. 'Idiopathic' means the cause is unknown. The scarring replaces the elastic air sacs of the lung with fibrous tissue, making it harder to breathe and reducing the ability to transfer oxygen into the blood. IPF primarily affects men over 60 with a history of smoking, but it can occur in non-smokers and women as well.

IPF symptoms develop gradually: progressive shortness of breath (especially with exertion), a persistent dry hacking cough, fatigue, unexplained weight loss, and clubbing of the fingers. A distinctive finding is Velcro-like crackles at the lung bases on exam. Many patients are misdiagnosed with heart failure or COPD for years before IPF is identified.

Both are FDA-approved antifibrotics that slow FVC decline by approximately 50% vs placebo. They work via different mechanisms: Ofev (nintedanib) is a tyrosine kinase inhibitor blocking growth factor signaling (PDGF, VEGF, FGF receptors). Esbriet (pirfenidone) has both antifibrotic and anti-inflammatory properties. Side effects differ: Ofev causes GI side effects (diarrhea) in ~60% of patients; Esbriet causes photosensitivity and nausea. Generic pirfenidone is now available and may be preferred for cost.

No — there is no cure for IPF. The only potential cure is lung transplantation for carefully selected patients. Both Esbriet and Ofev slow the rate of lung function decline but do not stop or reverse fibrosis. Oxygen therapy improves exercise tolerance as disease advances. Pulmonary rehabilitation improves functional capacity. New therapies targeting specific fibrotic pathways are in active clinical development.

The strongest risk factors are: age over 60 (peak incidence 70-74); male sex (roughly twice as common); cigarette smoking (past or current); occupational exposures (silica, asbestos, wood dust, metal dust); and genetic factors including MUC5B promoter variants and telomere-related gene mutations (TERT, TERC). GERD is also strongly associated with IPF, likely from microaspiration.

IPF should be managed by a pulmonologist with expertise in interstitial lung diseases (ILDs). A multidisciplinary team (MDT) discussion involving a pulmonologist, radiologist, and pathologist is the gold standard for confirming the IPF diagnosis. The Pulmonary Fibrosis Foundation (pulmonaryfibrosis.org) maintains a directory of care centers with ILD expertise.